Bright Minds Biosciences Inc.

Equities

DRUG

CA10919W4056

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 20:28:33 06/03/2026 GMT			5-day change	1st Jan Change
102.71 ^CAD	0.00%		-7.49%	-6.99%

02-13	Bright Minds Biosciences Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
01-09	Bright Minds Biosciences Closes its US$175 Million Public Offering	MT

Bright Minds Biosciences Inc. Reports Earnings Results for the Full Year Ended September 30, 2025

Published on 12/23/2025 at 10:27 pm GMT

S&P Capital IQ

BRIGHT MINDS BIOSCIENCES INC.

0.00%

Bright Minds Biosciences Inc. reported earnings results for the full year ended September 30, 2025. For the full year, the company reported net loss was CAD 12.23 million compared to CAD 2.8 million a year ago. Basic loss per share from continuing operations was CAD 1.78 compared to CAD 0.65 a year ago.

Latest news about Bright Minds Biosciences Inc.

02-13	Bright Minds Biosciences Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
01-09	Bright Minds Biosciences Closes its US$175 Million Public Offering	MT
01-09	Bright Minds Biosciences Closes $175.1 Million Stock Offering	MT
01-08	Bright Minds Biosciences Prices $175 Million Stock Offering	MT
01-08	Bright Minds Biosciences announces pricing of upsized US$175 million public offering of common stock at $90.00 per share	RE
01-06	Bright Minds Biosciences Launches US$100 Million Public Offering	MT
01-06	Bright Minds Biosciences Launches $100 Million Public Offering	MT
01-06	Bright Minds Biosciences Inc. Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies	CI
01-06	Bright Minds Biosciences Says Phase 2 Trial Results of BMB-101 Show 'Robust' Reduction in Seizure	MT
01-05	Bright Minds to announce topline results for BMB-101 phase 2 trial on Jan 6	RE
12-23	Bright Minds Biosciences Inc. Reports Earnings Results for the Full Year Ended September 30, 2025	CI
11-17	Bright Minds Biosciences Inc. Expands Scientific Advisory Board	CI
11-06	Bright Minds Biosciences Inc. Initiates New Prader-Willi Syndrome Program	CI
22/09/25	Bright Minds Biosciences Inc.(NasdaqCM:DRUG) added to S&P Global BMI Index	CI
05/09/25	Bright Minds Biosciences Enters Deal for $100 Million At-The-Market Offering	MT

Chart Bright Minds Biosciences Inc.

Duration

Period

DRUG: Dynamic Chart

Company Profile

Bright Minds Biosciences Inc. is a biotechnology company, which is engaged in developing treatments for patients with neurological and psychiatric disorders. The Company is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The Company has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.

Employees

Sector

Biotechnology & Medical Research

More about the company